Rein Therapeutics Inc (RNTX)
Rein Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for unmet medical needs in orphan pulmonary and fibrosis indications in the United States. Its lead candidate, LTI-03, is a peptide in Phase 1b testing for idiopathic pulmonary fibrosis. The company also advances LTI-01, a proenzyme that has completed Phase 1b and Phase 2a studies in loculated pleural effusion patients. Additional pipeline programs include preclinical work in cystic fibrosis, a peptide program targeting caveolin-1 for systemic fibrosis, and LTI-05, an epithelial sodium channel program for cystic fibrosis. Founded in 2001 and headquartered in Austin, Texas, the company was formerly known as Aileron Therapeutics, Inc. before adopting its current name in February 2007.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RNTX
|
$0.59
|
-25.2% Downside
|
Overvalued
|
$6
|
655.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 6, 2026
|
6.7x
|
68.556 M
|
69.917 M
|
0.0%
|
76.3%
|
-9.4
|
37.8%
|
